Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,787.90 | 44.30 | 0.51% |
| CAC 40 | 7,691.55 | 134.24 | 1.78% |
| DAX 40 | 24,033.22 | 383.92 | 1.62% |
| Dow JONES (US) | 43,819.27 | 432.43 | 1.00% |
| FTSE 100 | 8,798.91 | 63.31 | 0.72% |
| HKSE | 24,185.15 | 99.00 | -0.41% |
| NASDAQ | 20,273.46 | 105.55 | 0.52% |
| Nikkei 225 | 40,755.57 | 604.78 | 1.51% |
| NZX 50 Index | 12,573.99 | 9.60 | -0.08% |
| S&P 500 | 6,173.07 | 32.05 | 0.52% |
| S&P/ASX 200 | 8,560.10 | 45.90 | 0.54% |
| SSE Composite Index | 3,431.18 | 6.95 | 0.20% |